background
coalit
epidem
prepared
innov
cepi
launch
call
propos
cfp
vaccin
develop
lassa
mer
nipah
cepi
face
complex
decis
involv
confront
tradeoff
multipl
object
divers
stakehold
perspect
uncertainti
vaccin
perform
object
studi
report
multicriteria
decis
analysi
mcda
test
cepi
decis
method
consult
cepi
scientif
advisori
committe
sac
document
review
help
identifi
structur
criteria
evalu
propos
forti
four
subjectmatt
expert
assess
perform
propos
multipl
criteria
sac
prefer
elicit
via
survey
employ
adapt
swingweight
techniqu
incorpor
measur
valu
costtovalu
mont
carlo
simul
estim
overal
valu
rank
probabl
valu
costtovalu
propos
result
review
assess
sac
prefer
vari
significantli
despit
uncertainti
prefer
propos
emerg
analysi
sac
recommend
basi
valu
costtovalu
case
sac
recommend
deviat
analysi
less
emphasi
costtovalu
budget
seem
underestim
applic
emphasi
likelihood
gener
vaccin
target
pathogen
versu
platform
potenti
unknown
pathogen
emphasi
fund
divers
platform
per
pathogen
conclus
despit
vaccin
perform
uncertainti
stakehold
prefer
heterogen
mcda
distinguish
option
way
broadli
correspond
decis
diverg
mcda
sac
point
potenti
updat
need
model
platform
divers
tradeoff
keyword
cepi
epidem
infecti
diseas
health
research
prioriti
set
multicriteria
decis
analysi
research
develop
vaccin
open
access
articl
term
creativ
common
attribut
licens
permit
use
distribut
reproduct
medium
provid
origin
work
properli
cite
follow
success
vaccin
research
develop
r
respons
westafrican
ebola
epidem
grobusch
goorhui
world
health
organ
priorit
epidem
infecti
diseas
eid
like
caus
sever
outbreak
near
futur
vaccin
prevent
eid
outbreak
becom
humanitarian
crise
cepi
kieni
et
al
howev
market
incent
fail
sustain
r
effort
area
plotkin
new
entiti
coalit
epidem
prepared
innov
cepi
set
us
billion
invest
target
support
develop
vaccin
contribut
world
prepared
eid
outbreak
cepi
one
cepi
first
busi
plan
target
advanc
develop
two
three
vaccin
candid
prioriti
eid
preclin
end
earli
clinic
safeti
immunogen
test
phase
iia
cepi
cepi
aim
address
justincas
r
prepared
gap
associ
lack
phase
iibiiireadi
eid
vaccin
advanc
epidem
outbreak
like
funder
pharmaceut
r
cepi
face
challeng
priorit
limit
resourc
order
meet
inher
riski
r
target
aurentz
kirschbaum
thuneck
evid
suggest
averag
probabl
success
advanc
vaccin
candid
preclin
end
phase
ii
less
pronker
weenen
commandeur
claassen
osterhau
addit
larg
cost
dimasi
grabowski
hansen
long
timelin
russel
gronwal
involv
develop
vaccin
make
invest
decis
space
tremend
complex
complex
compound
fact
commerci
object
lack
field
eid
vaccin
commerci
valu
alon
insuffici
criterion
make
pharmaceut
r
invest
decis
antonijev
cioff
perezescobedo
azzaropantel
pibouleau
phillip
bana
e
costa
address
busi
plan
target
line
mission
scope
cepi
launch
competit
call
propos
cfp
late
januari
support
develop
vaccin
r
three
prioriti
eid
lassa
viru
middl
east
respiratori
syndrom
coronaviru
merscov
nipah
viru
rational
invest
vaccin
r
project
would
improv
likelihood
gener
vaccin
relev
use
respons
eid
well
improv
likelihood
platform
technolog
support
vaccin
would
suitabl
use
vaccin
develop
newli
unexpectedli
emerg
eid
evalu
propos
receiv
respons
call
face
sever
challeng
first
pharmaceut
r
portfolio
manag
involv
consid
multipl
criteria
includ
organiz
capabl
technic
manufactur
feasibl
develop
timelin
cost
align
target
product
profil
tpp
aurentz
et
al
bodegreuel
nickisch
seget
instanc
advoc
use
ideal
tpp
prefer
product
characterist
ppc
tailor
eid
outbreak
prepared
need
determin
use
potenti
vaccin
guid
r
prioriti
field
second
stakehold
opinion
vari
rel
import
differ
object
cepi
board
ultim
decisionmak
author
cepi
r
invest
independ
multimemb
scientif
advisori
committe
sac
advis
cepi
board
secretariat
r
invest
make
technic
recommend
project
fund
composit
sac
divers
time
deliber
describ
includ
nine
repres
govern
regul
seven
industri
member
eight
academ
four
repres
nonprofit
r
organ
cepi
context
multipl
tradeoff
heterogen
stakehold
perspect
multicriteria
decis
analysi
mcda
potenti
improv
qualiti
decis
make
viergev
gougla
tromp
mcda
becom
increasingli
popular
health
valuat
thokala
et
al
applic
numer
across
varieti
area
health
adunlin
diabi
xiao
associ
decis
problem
drake
de
hart
monleon
toro
valentim
marsh
et
al
thokala
et
al
mcda
offer
ration
transpar
approach
prioriti
set
simultan
consid
relev
criteria
avoid
ad
hoc
decis
baltussen
niessen
multipl
stakehold
divers
perspect
mcda
make
relev
conflict
explicit
help
decis
maker
understand
consid
impact
decis
phillip
bana
e
costa
timmi
black
rappuoli
use
mcda
increasingli
advoc
vaccin
r
barrochi
black
rappuoli
timmi
et
al
howev
knowledg
one
mcda
framework
appli
support
priorit
vaccin
r
see
instanc
phelp
et
al
kloeber
madhavan
et
al
madhavan
et
al
madhavan
et
al
framework
place
emphasi
differ
attribut
burden
diseas
difficult
appli
cepi
context
given
sporad
unpredict
natur
eid
moreov
lend
easili
estim
valu
vaccin
r
adjust
probabl
success
po
earli
stage
riski
vaccin
candid
assum
sourc
prefer
constraint
relev
cepi
decis
context
mcda
framework
develop
accord
ispor
good
practic
guidelin
inform
priorit
eid
vaccin
r
propos
support
cepi
cfp
decis
test
sac
recommend
studi
report
applic
mcda
framework
result
anonym
confidenti
restrict
associ
ongo
contract
negoti
cepi
develop
select
propos
fund
analysi
focus
full
propos
select
cepi
sac
extend
review
follow
initi
review
preliminari
propos
cepi
propos
combin
budget
us
million
review
cepi
march
may
seventeen
propos
preclin
develop
phase
one
propos
clinic
phase
aim
cepi
fund
would
advanc
end
clinic
phase
propos
cover
three
differ
type
diseas
lassa
mer
nipah
propos
budget
rang
us
million
us
million
median
cost
us
million
propos
timefram
end
clinic
phase
rang
year
median
timefram
year
due
confidenti
restrict
individu
propos
budget
timefram
report
howev
budget
timefram
use
gener
valu
framework
present
propos
name
diseas
classif
anonym
throughout
remaind
manuscript
propos
label
platform
type
label
seven
propos
cover
diseas
seven
propos
cover
diseas
four
propos
cover
diseas
goal
undertak
quantit
valuat
rank
propos
criteria
interest
sac
assum
propos
could
fund
given
resourc
avail
remaind
section
provid
stepbystep
overview
model
approach
adopt
detail
provid
data
step
narrow
list
criteria
combin
criteria
valu
framework
member
sac
cepi
secretariat
staff
ask
first
email
survey
group
discuss
januari
determin
whether
factor
relev
cfp
decis
captur
criteria
relationship
criteria
whether
criteria
remov
regroup
overlap
irrelev
follow
engag
overal
valu
vi
estim
describ
equat
tabl
criteria
defin
probabl
measur
scale
experi
trackrecord
likelihood
applic
suffici
compet
deliv
propos
activ
project
given
propos
feasibl
likelihood
develop
candid
vaccin
phase
ii
technic
feasibl
given
propos
manufactur
scalabl
speed
likelihood
vaccin
candid
manufactur
scalabl
timefram
volum
respond
outbreak
given
propos
use
potenti
cfp
target
pathogen
vaccin
candid
success
develop
manufactur
likelihood
meet
cepi
target
product
profil
relev
use
emerg
given
propos
use
potenti
new
pathogen
vaccin
candid
success
develop
manufactur
likelihood
platform
technolog
support
candid
vaccin
suitabl
use
vaccin
develop
newli
emerg
pathogen
given
propos
valu
framework
present
equat
present
approv
sac
februari
togeth
propos
criteria
descript
measur
scale
apprais
question
review
see
tabl
overal
likelihood
project
gener
vaccin
relev
use
respons
one
cfp
target
pathogen
probabl
success
vaccin
develop
preclin
phase
ii
criteria
time
probabl
use
cfp
target
pathogen
likelihood
platform
technolog
suitabl
vaccin
develop
new
pathogen
overal
likelihood
platform
technolog
support
vaccin
suitabl
use
respons
newli
emerg
andor
unexpect
pathogen
probabl
success
vaccin
develop
preclin
phase
ii
criteria
time
probabl
use
new
pathogen
potenti
support
vaccin
develop
pathogen
criteria
combin
multipl
step
criterion
review
ask
defin
like
worstcas
bestcas
perform
propos
scale
see
data
detail
order
determin
degre
homogen
assess
provid
differ
review
interreview
assess
variabl
test
conduct
specif
criterion
perform
estim
worstcas
like
bestcas
follow
step
undertaken
first
perform
mean
across
review
assess
given
propos
calcul
second
differ
mean
review
perform
estim
given
propos
calcul
third
step
repeat
propos
fourth
review
averag
deviat
perform
estim
perform
mean
across
assess
propos
estim
fifth
basi
cicchetti
classif
review
variabl
determin
good
averag
deviat
less
perform
mean
excel
deviat
less
perform
mean
across
assess
propos
seven
review
found
least
one
averag
worstcas
like
bestcas
perform
estim
deviat
equival
perform
mean
across
assess
propos
total
estim
deviat
observ
account
total
number
worstcas
like
bestcas
perform
estim
collect
impact
remov
result
analysi
test
found
substanti
chang
perform
propos
step
estim
partial
valu
pv
pv
partial
valu
function
elicit
sac
member
use
onlin
survey
respond
survey
recipi
function
defin
use
midvalu
split
methoda
widelyus
decompos
scale
techniqu
also
known
bisect
method
von
winterfeldt
edward
elicit
valu
midpoint
perform
rang
point
figur
question
procedur
appli
elicit
partial
valu
sac
member
answer
six
pairwis
choic
question
iter
approach
valu
midpoint
instanc
first
question
consid
follow
two
propos
differ
start
likelihood
gener
vaccin
relev
use
respons
one
cfp
target
pathogen
imagin
given
opportun
improv
perform
one
propos
follow
option
would
prefer
option
improv
propos
likelihood
gener
vaccin
relev
use
respons
one
cfp
target
pathogen
increas
x
option
b
improv
propos
b
likelihood
gener
vaccin
relev
use
respons
one
cfp
target
pathogen
increas
x
first
question
x
set
midpoint
perform
rang
respond
indiffer
partial
valu
function
consid
linear
question
ask
respond
chose
option
option
b
valu
x
updat
accord
logic
defin
section
data
pairwis
choic
question
identifi
within
rang
assum
midpoint
rang
basi
partial
valu
function
could
defin
see
section
data
step
estim
weight
w
w
weight
elicit
use
tradeoff
method
von
winterfeldt
edward
case
rang
perform
sac
member
use
onlin
survey
respond
survey
recipi
iter
pairwis
comparison
use
identifi
valu
b
respond
would
indiffer
improv
improv
specif
follow
question
ask
via
onlin
survey
figur
partial
valu
function
likelihood
gener
vaccin
one
cfp
target
pathogen
illustr
consid
follow
two
propos
would
prefer
propos
likelihood
gener
vaccin
relev
use
respons
one
target
pathogen
likelihood
technolog
suitabl
use
vaccin
develop
newli
emergingunexpect
pathogen
propos
b
likelihood
gener
vaccin
relev
use
respons
one
target
pathogen
likelihood
technolog
suitabl
use
vaccin
develop
newli
emergingunexpect
pathogen
initi
valu
set
vari
depend
respons
defin
section
data
six
question
valu
b
defin
within
rang
defin
section
data
assum
valu
b
midpoint
rang
section
data
provid
detail
b
use
estim
weight
step
elicit
time
prefer
r
time
prefer
estim
use
choic
exercis
design
identifi
valu
c
sac
member
indiffer
z
chanc
success
deliv
propos
within
year
chanc
within
year
follow
question
format
implement
sac
member
onlin
survey
consid
follow
two
propos
would
prefer
valu
z
first
question
set
vari
depend
respons
manner
describ
section
data
six
question
valu
c
identifi
within
rang
describ
section
data
assum
c
took
valu
midpoint
rang
section
data
provid
detail
c
use
estim
estim
discount
rate
step
deal
uncertainti
review
perform
input
sac
prefer
subject
signific
variat
uncertainti
incorpor
mcda
via
mont
carlo
simul
model
run
time
time
draw
differ
input
follow
perform
input
criteria
iter
randomli
select
one
review
randomli
select
perform
estim
perform
distribut
sac
prefer
iter
randomli
drew
partial
valu
weight
time
prefer
singl
sac
member
distribut
mean
confid
interv
perform
v
estim
iter
simul
comparison
propos
within
iter
allow
rank
propos
analys
across
iter
allow
estim
rank
probabl
propos
step
criteria
perform
vaccin
r
propos
present
tabl
uncertainti
perform
mean
substanti
overlap
confid
interv
around
propos
perform
likelihood
gener
suitabl
vaccin
one
cfp
target
pathogen
likelihood
platform
technolog
suitabl
vaccin
develop
new
pathogen
assum
project
select
figur
plot
likelihood
propos
rank
top
basi
discount
valu
versu
costtovalu
consider
budget
affect
rank
output
analysi
fund
propos
second
sac
place
less
emphasi
costtovalu
case
propos
budget
consid
unrealist
one
implic
propos
small
budget
whose
overal
valu
otherwis
low
priorit
third
sac
deliber
point
toward
structur
implic
mcda
novel
combin
multiplicativeaddit
model
structur
adopt
mcda
applic
healthcar
multipl
compon
despit
concern
health
technolog
assess
meet
analyt
requir
addit
model
marsh
sculpher
caro
tervonen
multipl
compon
model
implicitli
gave
equal
weight
criteria
wherea
sac
deliber
seem
emphas
criteria
other
eg
fourth
sac
recommend
could
impli
altern
weight
use
model
specif
even
greater
weight
given
elicit
survey
weight
model
elicit
use
iter
comparison
improv
pair
criteria
method
chosen
due
small
sampl
size
provid
insuffici
power
discret
choic
experi
desir
elicit
ordin
data
survey
format
tervonen
et
al
result
averag
weight
given
though
also
signific
variat
sac
member
weight
given
variat
one
possibl
would
reconcil
sac
recommend
result
mcda
sac
member
gave
higher
weight
influenti
deliber
conclus
analysi
report
studi
demonstr
possibl
use
mcda
support
priorit
vaccin
r
invest
complex
decis
context
character
outcom
uncertainti
varianc
expect
perform
vaccin
heterogen
stakehold
prefer
intent
aid
rather
replac
delib
stakehold
process
prescrib
decis
find
illustr
mcda
help
differenti
invest
support
decis
make
